Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. (Q30450038)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

neurofibromatosis type II

9 February 2020

main subject

phase II clinical trial

0 references

1 reference

inferred from title

author

Matthias A. Karajannis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Judith D. Goldberg

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Jeffrey Allen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Geneviève Legault

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Mari Hagiwara

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Marc S Ballas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Krysten Brown

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Annette O Nusbaum

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Tsivia Hochman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Kevin M Koch

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

John G Golfinos

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

J Thomas Roland

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

27 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1163-1170

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

9 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Contact-dependent inhibition of EGFR signaling by Nf2/Merlin

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

The natural history of vestibular schwannoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Optimal two-stage designs for phase II clinical trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy

20 June 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS146

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS146

Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS146

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS146

Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS146

Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS146

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOS146

A clinical study of type 2 neurofibromatosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3424212

Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation

26 November 2018

1 reference

12 December 2020

Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety

1 reference

12 December 2020

Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion

1 reference

12 December 2020

The Natural History of Vestibular Schwannoma

1 reference

12 December 2020

Identifiers

DOI

10.1093/NEUONC/NOS146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

22844108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22844108%20AND%20SRC:MED&resulttype=core&format=json